Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Schmid, SC; Koll, FJ; Beckert, F; Seitz, AK.
[Immuno-oncological approaches in the perioperative therapy of muscle invasive bladder cancer].
Urologe A. 2020; 59(7): 790-796.
Doi: 10.1007/s00120-020-01234-5
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Koll Florestan Johannes
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Perioperative chemotherapy has become a standard treatment for muscle invasive bladder cancer and is recommended by national and international guidelines. The treatment of metastatic urothelial cancer evolved by the use of immune-modulating therapies like checkpoint inhibitors. Many clinical trials have been initiated which try to evaluate the role of immune checkpoint inhibition in the neoadjuvant and adjuvant setting. These trials focus not only on monotherapy, but also on the combination of checkpoint inhibitors with classical chemotherapy or with local radiation therapy (radioimmunotherapy). In neoadjuvant radioimmunotherapy, the radiation is supposed to act as a sensitizer for the systemic effects of checkpoint inhibition, in addition to the local effects. This review presents and discusses current trials and published results for perioperative immunomodulating treatment-alone or in combination-in muscle invasive bladder cancer.
- Find related publications in this database (using NLM MeSH Indexing)
- Antineoplastic Agents - therapeutic use
- Antineoplastic Agents, Immunological - adverse effects, therapeutic use
- Carcinoma, Transitional Cell - immunology, pathology, therapy
- Chemotherapy, Adjuvant - administration & dosage
- Combined Modality Therapy - administration & dosage
- Cystectomy - administration & dosage
- Humans - administration & dosage
- Immunotherapy - administration & dosage
- Neoadjuvant Therapy - administration & dosage
- Perioperative Care - methods
- Practice Guidelines as Topic - administration & dosage
- Programmed Cell Death 1 Receptor - immunology, therapeutic use
- Treatment Outcome - administration & dosage
- Urinary Bladder Neoplasms - immunology, pathology, therapy
- Urologic Neoplasms - immunology, pathology, therapy
- Find related publications in this database (Keywords)
- Urothelial cancer
- Immune modulating therapy
- Checkpoint inhibitor
- Radioimmunotherapy
- PD1
- PD-L1